Multiple Myeloma

>

Latest News

Real-world data show that CAR T-cell therapy may be considered for eligible patients with relapsed/refractory multiple myeloma harboring CNS involvement.
Data Support Real-World Use of Ide-cel in R/R CNS Multiple Myeloma

December 12th 2024

Real-world data show that CAR T-cell therapy may be considered for eligible patients with relapsed/refractory multiple myeloma harboring CNS involvement.

ORR, DOR, and Safety Outcomes with Lisaftoclax Combo Were Strong in RRMM
ORR, DOR, and Safety Outcomes with Lisaftoclax Combo Were Strong in RRMM

December 10th 2024

Overall MRD Negativity Rates Improved with Cilta-cel vs SOC in MM
Overall MRD Negativity Rates Improved with Cilta-cel vs SOC in MM

December 10th 2024

Reduction in AEs by Pelabresib With Ruxolitinib in JAK-Naive Myelofibrosis
Reduction in AEs by Pelabresib With Ruxolitinib in JAK-Naive Myelofibrosis

December 10th 2024

Superior Rates of MRD Upheld by Isatuximab Combo in Multiple Myeloma
Superior Rates of MRD Upheld by Isatuximab Combo in Multiple Myeloma

December 10th 2024